Top

10-27-2004 | Type 2 diabetes | Article

A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)

Journal: Diabetologia

Authors: P. M. Clarke, A. M. Gray, A. Briggs, A. J. Farmer, P. Fenn, R. J. Stevens, D. R. Matthews, I. M. Stratton, R. R. Holman, on behalf of the UK Prospective Diabetes Study (UKPDS) Group

Publisher: Springer-Verlag

Abstract

Aims/hypothesis

The aim of this study was to develop a simulation model for Type 2 diabetes that can be used to estimate the likely occurrence of major diabetes-related complications over a lifetime, in order to calculate health economic outcomes such as quality-adjusted life expectancy.

Methods

Equations for forecasting the occurrence of seven diabetes-related complications and death were estimated using data on 3642 patients from the United Kingdom Prospective Diabetes Study (UKPDS). After examining the internal validity, the UKPDS Outcomes Model was used to simulate the mean difference in expected quality-adjusted life years between the UKPDS regimens of intensive and conventional blood glucose control.

Results

The model’s forecasts fell within the 95% confidence interval for the occurrence of observed events during the UKPDS follow-up period. When the model was used to simulate event history over patients’ lifetimes, those treated with a regimen of conventional glucose control could expect 16.35 undiscounted quality-adjusted life years, and those receiving treatment with intensive glucose control could expect 16.62 quality-adjusted life years, a difference of 0.27 (95% CI: −0.48 to 1.03).

Conclusions/interpretations

The UKPDS Outcomes Model is able to simulate event histories that closely match observed outcomes in the UKPDS and that can be extrapolated over patients’ lifetimes. Its validity in estimating outcomes in other groups of patients, however, remains to be evaluated. The model allows simulation of a range of long-term outcomes, which should assist in informing future economic evaluations of interventions in Type 2 diabetes.

Eastman RC, Javitt JC, Herman WH et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20:725–734PubMed

Brown JB, Russell A, Chan W, Pedula K, Aickin M (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50 [Suppl 3]:S15–S46

Palmer AJ, Brandt A, Valerio G, Weiss C, Stock H, Wenzel H (2000) Outline of a diabetes disease management model. Principles and applications. Diabetes Res Clin Pract 50 [Suppl 3]:S47–S56

Bagust A, Hopkinson PK, Maier W, Currie CJ (2001) An economic model of the long-term health care burden of Type II diabetes. Diabetologia 44:2140–2155CrossRefPubMed

CDC Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542–2551PubMed

DCCT (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 276:1409–1415PubMed

Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341–344CrossRefPubMed

UKPDS Group (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMed

Adler AI, Stratton IM, Neil HA et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419CrossRefPubMed

10.

Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef

11.

Kothari V, Stevens RJ, Adler AI et al. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776–1781CrossRefPubMed

12.

UKPDS Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890PubMed

13.

UKPDS Group (1994) Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544PubMed

14.

Hougaard P (2000) Analysis of multivariate survival data (Statistics for biology and health). Springer, Berlin

15.

American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21:296–309PubMed

16.

Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 159:1873–1880CrossRefPubMed

17.

Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312–318PubMed

18.

Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG (1999) A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 22:1036–1042PubMed

19.

Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ (1997) Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278:2069–2074CrossRefPubMed

20.

UKPDS Group (2003) Development and progression of nephropathy in Type 2 diabetes: observation and modelling from the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232CrossRefPubMed

21.

Cupples LA, D’Agostino RB, Anderson K, Kannel WB (1988) Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med 7:205–222PubMed

22.

Altman DG, De Stavola BL (1994) Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13:301–341PubMed

23.

Greene WH (1997) Econometric analysis, 4 edn. Prentice-Hall, London

24.

UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefPubMed

25.

Panzram G (1987) Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123–131PubMed

26.

Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med 339:380–386CrossRefPubMed

27.

EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRefPubMed

28.

Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349CrossRefPubMed

29.

Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453–473CrossRefPubMed

30.

Gray A, Raikou M, McGuire A et al. (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373–1378CrossRefPubMed

31.

Schafer JL (1999) Multiple imputation: a primer. Stat Methods Med Res 8:3–15CrossRefPubMed

32.

Government Actuary’s Department (2003) Interim life tables 1999–2001. The Stationery Office, London

33.

Williams R, Van Gaal L, Lucioni C (2002) Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 45:S13–S17CrossRefPubMed

34.

Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293–298CrossRefPubMed

35.

Menotti A, Lanti M, Puddu PE (2000) Long-term time-related predictivity of coronary events as a function of a single measurement of serum cholesterol and systolic blood pressure. Acta Cardiol 55:87–93PubMed

36.

Stevens R, Adler A, Gray A, Briggs A, Holman R (2000) Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50 [Suppl 3]:S5–S13

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »